Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA

Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. R...

Full description

Saved in:
Bibliographic Details
Published in:Current bladder dysfunction reports 2018-06, Vol.13 (2), p.25-30
Main Authors: Kirby, Anna C., Kellogg, Elizabeth S.
Format: Article
Language:English
Subjects:
Geriatrics/Gerontology
Gynecology
Medicine
Medicine & Public Health
Overactive Bladder (U Lee and S Adelstein
Section Editors
Topical Collection on Overactive Bladder
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c266t-9f7c8aad26e58c7df4a8960003e96107026880fc16232e6da24fd3f56dd8ca7f3
container_end_page 30
container_issue 2
container_start_page 25
container_title Current bladder dysfunction reports
container_volume 13
creator Kirby, Anna C.
Kellogg, Elizabeth S.
description Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications. Summary Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.
doi_str_mv 10.1007/s11884-018-0462-7
format article
fullrecord <record><control><sourceid>crossref_sprin</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s11884_018_0462_7</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1007_s11884_018_0462_7</sourcerecordid><originalsourceid>FETCH-LOGICAL-c266t-9f7c8aad26e58c7df4a8960003e96107026880fc16232e6da24fd3f56dd8ca7f3</originalsourceid><addsrcrecordid>eNp9kN1OAjEQhTdGExF9AO_6AFbbLnS73iHxh4SACXC9Kf3BkqUl0y5RH8zncwHDpVdzkvnOmcnJsltK7ikhxUOkVIgeJlRg0uMMF2dZh5Y5xQVj5PykKbvMrmJcE9In_ZJ1sp85GK8jch4tkqvdt0wueBQsmn840HjsvGmlAbl1JiIbAE2Cx940EFbGO4Wmu3apktsZ9FRLrQ08oplUIGs02VOboJv6kHqH3g247T6sRnO3dAcEWuMsuc0Jkl6jkU8gtUnQxPbi1MtlSE3tfLNJ4dP5wXV2YWUdzc3f7GaLl-f58A2Pp6-j4WCMFeM84dIWSkipGTd9oQpte1KUnBCSm5JTUhDGhSBWUc5yZriWrGd1bvtca6FkYfNuRo-5CkKMYGy1BbeR8FVRUu2Lr47FV23x1b74qmg97OiJLetXBqp1aMC3b_5j-gWy1YtH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA</title><source>Springer Link</source><creator>Kirby, Anna C. ; Kellogg, Elizabeth S.</creator><creatorcontrib>Kirby, Anna C. ; Kellogg, Elizabeth S.</creatorcontrib><description>Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications. Summary Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.</description><identifier>ISSN: 1931-7212</identifier><identifier>EISSN: 1931-7220</identifier><identifier>DOI: 10.1007/s11884-018-0462-7</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Geriatrics/Gerontology ; Gynecology ; Medicine ; Medicine &amp; Public Health ; Overactive Bladder (U Lee and S Adelstein ; Section Editors ; Topical Collection on Overactive Bladder ; Urology</subject><ispartof>Current bladder dysfunction reports, 2018-06, Vol.13 (2), p.25-30</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c266t-9f7c8aad26e58c7df4a8960003e96107026880fc16232e6da24fd3f56dd8ca7f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Kirby, Anna C.</creatorcontrib><creatorcontrib>Kellogg, Elizabeth S.</creatorcontrib><title>Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA</title><title>Current bladder dysfunction reports</title><addtitle>Curr Bladder Dysfunct Rep</addtitle><description>Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications. Summary Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.</description><subject>Geriatrics/Gerontology</subject><subject>Gynecology</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Overactive Bladder (U Lee and S Adelstein</subject><subject>Section Editors</subject><subject>Topical Collection on Overactive Bladder</subject><subject>Urology</subject><issn>1931-7212</issn><issn>1931-7220</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kN1OAjEQhTdGExF9AO_6AFbbLnS73iHxh4SACXC9Kf3BkqUl0y5RH8zncwHDpVdzkvnOmcnJsltK7ikhxUOkVIgeJlRg0uMMF2dZh5Y5xQVj5PykKbvMrmJcE9In_ZJ1sp85GK8jch4tkqvdt0wueBQsmn840HjsvGmlAbl1JiIbAE2Cx940EFbGO4Wmu3apktsZ9FRLrQ08oplUIGs02VOboJv6kHqH3g247T6sRnO3dAcEWuMsuc0Jkl6jkU8gtUnQxPbi1MtlSE3tfLNJ4dP5wXV2YWUdzc3f7GaLl-f58A2Pp6-j4WCMFeM84dIWSkipGTd9oQpte1KUnBCSm5JTUhDGhSBWUc5yZriWrGd1bvtca6FkYfNuRo-5CkKMYGy1BbeR8FVRUu2Lr47FV23x1b74qmg97OiJLetXBqp1aMC3b_5j-gWy1YtH</recordid><startdate>20180601</startdate><enddate>20180601</enddate><creator>Kirby, Anna C.</creator><creator>Kellogg, Elizabeth S.</creator><general>Springer US</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20180601</creationdate><title>Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA</title><author>Kirby, Anna C. ; Kellogg, Elizabeth S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c266t-9f7c8aad26e58c7df4a8960003e96107026880fc16232e6da24fd3f56dd8ca7f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Geriatrics/Gerontology</topic><topic>Gynecology</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Overactive Bladder (U Lee and S Adelstein</topic><topic>Section Editors</topic><topic>Topical Collection on Overactive Bladder</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kirby, Anna C.</creatorcontrib><creatorcontrib>Kellogg, Elizabeth S.</creatorcontrib><collection>CrossRef</collection><jtitle>Current bladder dysfunction reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kirby, Anna C.</au><au>Kellogg, Elizabeth S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA</atitle><jtitle>Current bladder dysfunction reports</jtitle><stitle>Curr Bladder Dysfunct Rep</stitle><date>2018-06-01</date><risdate>2018</risdate><volume>13</volume><issue>2</issue><spage>25</spage><epage>30</epage><pages>25-30</pages><issn>1931-7212</issn><eissn>1931-7220</eissn><abstract>Purpose of Review To report on current and emerging trends in the use of third-line therapies for non-neurogenic overactive bladder (OAB). Recent findings The use of third-line therapies for OAB has been steadily increasing, but it appears that only a small percentage of OAB patients receive them. Recent research has found an increased risk of dementia associated with cumulative use of anticholinergic medications, including OAB antimuscarinic medications. Cost-effective analyses suggest that these third-line therapies may be worth considering prior to medications. Summary Research and efforts to improve adherence to current OAB guidelines are needed to increase their use by patients with refractory OAB. Whether or not the therapies we presently consider third line should actually be second line for some of our patients remains to be determined.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s11884-018-0462-7</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1931-7212
ispartof Current bladder dysfunction reports, 2018-06, Vol.13 (2), p.25-30
issn 1931-7212
1931-7220
language eng
recordid cdi_crossref_primary_10_1007_s11884_018_0462_7
source Springer Link
subjects Geriatrics/Gerontology
Gynecology
Medicine
Medicine & Public Health
Overactive Bladder (U Lee and S Adelstein
Section Editors
Topical Collection on Overactive Bladder
Urology
title Trends in Utilization of Third-Line Therapies for Non-neurogenic Overactive Bladder: Sacral Neuromodulation, Peripheral Tibial Nerve Stimulation, and Intradetrusor OnabotulinumtoxinA
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T12%3A53%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref_sprin&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trends%20in%20Utilization%20of%20Third-Line%20Therapies%20for%20Non-neurogenic%20Overactive%20Bladder:%20Sacral%20Neuromodulation,%20Peripheral%20Tibial%20Nerve%20Stimulation,%20and%20Intradetrusor%20OnabotulinumtoxinA&rft.jtitle=Current%20bladder%20dysfunction%20reports&rft.au=Kirby,%20Anna%20C.&rft.date=2018-06-01&rft.volume=13&rft.issue=2&rft.spage=25&rft.epage=30&rft.pages=25-30&rft.issn=1931-7212&rft.eissn=1931-7220&rft_id=info:doi/10.1007/s11884-018-0462-7&rft_dat=%3Ccrossref_sprin%3E10_1007_s11884_018_0462_7%3C/crossref_sprin%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c266t-9f7c8aad26e58c7df4a8960003e96107026880fc16232e6da24fd3f56dd8ca7f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true